



Date: 22 Feb, 2018

To,
Listing Department,
Dept. of Corporate Services,
Bombay Stock Exchange Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai: 400 001.

To,
General Manager,
National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai: 400 051.

Dear Sir/Madam,

Ref.:- Scrip Code - 532908 Scrip ID-SHARONBIO

Sub:- Financial Results for the quarter and nine months ended December 31, 2017.

Pursuant to Regulation 33 of the SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we would like to intimate the exchange that Resolution Professional on 22 February, 2018 has considered and approved the following:

- i) The Standalone Unaudited Financial Results of the Company with Limited Review Report for the quarter and nine months ended December 31, 2017.

The meeting of Resolution Professional held today, commenced at 3:00 pm and concluded at 7:50 pm.

Kindly find the same for your record & acknowledge the receipt for the same.

Thanking You,

Yours faithfully,
For Sharon Bio-Medicine Limited

Deepali Bhatia
Company Secretary & Compliance officer

Encl.: a/a



Sharon BIO-MEDICINE LTD.

An ISO-9001:2000
Certified Company



Extract of Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2017

(₹ in Lacs)

| PARTICULARS | Quarter Ended 31/12/2017 | Quarter Ended 31/12/2016 | Nine Months Ended 31/12/2017 |
|---|--------------------------------|--------------------------------|------------------------------------|
| | Unaudited | Unaudited | Unaudited |
| Total income from operations | 4,055.22 | 3,407.61 | 9,373.30 |
| Net Profit / (Loss) for the period (Before Tax, Exceptional and/or Extraordinary items) | 75.34 | (988.83) | (411.20) |
| Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items) | 69.17 | (1,003.87) | (9,455.20) |
| Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items) | 69.17 | (191.07) | (9,455.20) |
| Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 65.27 | (194.97) | (9,466.90) |
| Paid up Equity Share Capital (Face Value of Rs.2/- each) | 2,378.71 | 2,378.71 | 2,378.71 |
| Earnings Per share (before extraordinary items) | | | |
| (of 2/- each) Basic | 0.05 | (0.16) | (7.96) |
| Earnings Per share (after extraordinary items) | | | |
| (of 2/- each) Diluted | 0.05 | (0.16) | (7.96) |

Note: The above is an extract of the detailed format of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Standalone Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2017 are available on the Stock Exchange websites. (www.bseindia.com / www.nseindia.com) and Company's website www.sharonbio.com

For Sharon Bio-Medicine Ltd.

Dinkar Venkatasubramanian

SD/-

Resolution Professional

Savita Gowda

IP Registration no. IBBI/IPA-001/

Managing Director.

IP-P00003/2016-17/10011

Place : Mumbai.

Date : February 22, 2018

REGISTERED OFFICE & WORKS : W-34 & 34/1, MIDC, Taloja,
Dist. Raigad, Maharashtra (India).

CORP.: C-310/312, BSEL Tech Park, Opp. Vashi-Railway Station, Navi Mumbai – 400 703.

E-mail : investor_complaints@sharonbio.com, Website : www.sharonbio.com